FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.0	C. 20549
-----------------	----------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average to	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Walts Alan Edmund				2. Is Ele	2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ ELOX ]									all applic	cable) r	g Pers	son(s) to Iss 10% Ov	ner	
	OXX PHA	RMACEUTICAI	(Middle)													Other (s below)	pecify		
480 ARSENAL WAY, SUITE 130				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WATER	ΓOWN	MA	02472											X		iled by Mor	orting Perso n One Repo	ting Person One Reporting	
(City)		,	(Zip)													-			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Ins				ed (A) or str. 3, 4 an	d	5. Amount of Securities Beneficially Owned Following		Form (D) o	r Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
								Code V		Amount	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)				mst. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v			Date Exercisable		xpiration ate	Amo or Num of Title Shar							
Stock Options (Right to Buy)	\$4	01/30/2023			A		2,859		(1)	0	1/30/2033	Common Stock	2,859		\$0	2,859		D	

## **Explanation of Responses:**

1. The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.

/s/ Sumit Aggarwal, Attorney-01/31/2023 in-Fact for Alan Edmund Walts

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.